STAGE IVA LUNG CANCER AJCC V8
Clinical trials for STAGE IVA LUNG CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA LUNG CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA LUNG CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial aims to boost Radiation's power against brain tumors
Disease control OngoingThis early-stage study is testing a new drug called berzosertib, given alongside standard whole-brain radiation therapy. The main goal is to find the safest and most effective dose of the drug combination for patients whose lung cancer has spread to the brain. Researchers hope th…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC
-
Scientists test vitamin a boost to help immune system fight advanced lung cancer
Disease control OngoingThis early-stage study is testing a new combination treatment for advanced non-small cell lung cancer that has spread or returned. Researchers are combining a drug made from vitamin A (ATRA) with an immunotherapy drug (atezolizumab) to see if it is safe and to find the best dose.…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New Triple-Threat treatment trial aims to keep aggressive lung cancer at bay
Disease control OngoingThis trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers, especially a type called extensive-stage small cell lung cancer. The study first finds a safe dose, then compares the th…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThis study is testing a combination of three drugs for people with advanced lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to the usual treatment. The goal is to see if adding two antibody drugs (trastuzumab and necitumumab) to the stand…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
One-Two punch for lung cancer: can zapping tumors boost drug power?
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Cancer treatment moves home: trial tests telemedicine for lung cancer care
Disease control OngoingThis study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Doctors test custom drug matches for tough lung cancers
Disease control OngoingThis study aims to find the best next treatment for people with advanced ALK-positive non-small cell lung cancer that has worsened after initial targeted therapy. Doctors test a fresh tumor sample to identify specific genetic changes causing drug resistance, then match each patie…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
One-Shot radiation tested to zap remaining lung cancer cells
Disease control OngoingThis study is testing a new, faster way to give radiation after surgery for non-small cell lung cancer. Instead of weeks of daily treatments, doctors give one powerful, highly focused dose to try to kill any leftover cancer cells while aiming to spare healthy lung tissue. The mai…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for lung cancer patients after standard treatment fails
Disease control OngoingThis early-stage study is testing whether adding an experimental drug called minnelide to an existing lung cancer medication (osimertinib) is safe and might help patients whose cancer has continued to grow. The trial is for adults with advanced non-small cell lung cancer that has…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New combo attack on tough lung cancer
Disease control OngoingThis early study is testing a two-part treatment for advanced non-small cell lung cancer with a specific genetic change (ALK). First, patients take a targeted drug (brigatinib) to shrink tumors. Then, they receive focused radiation or surgery to try to eliminate any remaining can…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Zapping lung cancer: heat vs. scalpel in Head-to-Head trial
Disease control OngoingThis study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for Tough-to-Treat lung cancer: testing a Triple-Drug attack
Disease control OngoingThis study is testing if adding a new drug called pevonedistat to two standard chemotherapy drugs (carboplatin and paclitaxel) works better for people with advanced non-small cell lung cancer. It is for adults whose cancer has gotten worse after treatment with immunotherapy. The …
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Cancer vaccine teams up with immune drugs in fight against advanced tumors
Disease control OngoingThis trial is testing whether combining an experimental cancer vaccine (CIMAvax) with approved immunotherapy drugs (nivolumab or pembrolizumab) is safe and more effective for treating advanced non-small cell lung cancer or squamous head and neck cancer. The study aims to find the…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug duo enters first human trial for Tough-to-Treat lung cancer
Disease control OngoingThis is an early-stage trial testing a combination of two oral drugs, sapanisertib and telaglenastat, for patients with advanced non-small cell lung cancer that has spread and progressed after standard treatments. The main goals are to find the safest dose of the drug combination…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists test supercharged cord blood cells as new weapon against tough lung cancers
Disease control OngoingThis early-stage study is testing a new type of cell therapy for people with advanced non-small cell lung cancer that has spread and no longer responds to standard immunotherapy. Researchers are giving patients specially modified immune cells (called NK cells) taken from umbilica…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets genetic driver in advanced lung cancer
Disease control OngoingThis study is testing an oral drug called selpercatinib for people with advanced non-small cell lung cancer that has a specific genetic change called a RET fusion. The goal is to see how well the drug shrinks tumors and controls the cancer by blocking the abnormal protein driving…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Precision brain radiation study aims to spare thinking skills in cancer patients
Disease control OngoingThis study tests whether a precise form of radiation called stereotactic radiosurgery (SRS) can control lung cancer that has spread to the brain while better preserving patients' memory and thinking abilities. It compares SRS, which targets only the tumors, to standard whole-brai…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug duo aims to outsmart resistant lung cancer
Disease control OngoingThis trial is testing whether adding a new drug called LY3295668 to an existing lung cancer drug (osimertinib) can help control cancer that has stopped responding to standard treatment. It involves 32 adults with a specific type of advanced lung cancer (EGFR-mutant non-small cell…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New combo attack on tough lung cancers
Disease control OngoingThis study is testing a combination of two drugs, trametinib and pembrolizumab, for people with advanced non-small cell lung cancer that has come back or spread after previous treatments. The goal is to see if the drugs work better together to control the cancer and to find the s…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New Triple-Threat attack on aggressive lung cancer
Disease control OngoingThis study is testing a new combination of treatments for people with extensive-stage small cell lung cancer who haven't had treatment yet. It combines a targeted drug (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy, and radiation. The goal is to see if this…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New drug duo tested for Tough-to-Treat lung cancer
Disease control OngoingThis early-phase study is testing a combination of two drugs, brigatinib and bevacizumab, for patients with a specific type of advanced lung cancer (ALK-positive) that has worsened despite prior targeted therapy. The main goals are to find the safest dose and understand the side …
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
New hope for tough lung cancers: Triple-Threat treatment tested
Disease control OngoingThis study is testing a new combination of three drugs for people with advanced non-small cell lung cancer that has spread or come back after standard treatments failed. The goal is to see if mixing an immunotherapy drug, a drug that blocks tumor blood supply, and a chemotherapy …
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
Scientists test Four-Drug cocktail in fight against tough lung cancer
Disease control OngoingThis early-stage study is testing a combination of four drugs for people with a specific type of advanced lung cancer (ALK-positive). The main goals are to find the safest dose of the new drug, ensartinib, when given with three other cancer drugs, and to see what side effects occ…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
New pill targets 'Undruggable' cancer mutation in advanced lung cancer
Disease control OngoingThis study is testing an experimental pill called AMG 510 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The pill is designed to block this specific mutation, which can drive cancer growth, in patients whose cancer has wor…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
Nurses tackle the hidden fear that haunts advanced cancer patients
Symptom relief OngoingThis study is testing whether a special program led by nurses can help people with advanced lung or gynecologic cancer cope with intense fears about their illness getting worse. Participants will have five short video sessions over six weeks to learn worry management skills, set …
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Mar 30, 2026 14:31 UTC
-
Virtual therapy tested to ease lung cancer distress
Symptom relief OngoingThis study is testing an online support program designed to help women with lung cancer feel better emotionally and manage their symptoms. Participants are assigned to either a group learning mindfulness and coping skills or a group receiving educational information about lung ca…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Mar 20, 2026 14:48 UTC
-
New hope for cancer patients struggling to eat
Symptom relief OngoingThis study is testing whether a medication called anamorelin can help improve appetite and prevent weight loss in people with advanced lung cancer who have poor appetite. Researchers will compare anamorelin against a placebo (inactive pill) in 25 patients over 9 weeks. The study …
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Mar 16, 2026 15:25 UTC
-
Can blood tests tame Chemo's painful side effects?
Knowledge-focused TerminatedThis study aims to see if doctors can reliably measure the amount of a common chemotherapy drug (paclitaxel) in a patient's blood. The goal is to learn if tracking these levels can help find the right dose to fight cancer while reducing a severe side effect: nerve damage that cau…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC
-
Can a simple video unlock better cancer care decisions?
Knowledge-focused OngoingThis study is testing whether a short educational video can help patients with advanced cancer better understand tumor genomic testing. It involves 243 adults with metastatic breast or lung cancer who are already scheduled for this type of testing. Researchers will measure if wat…
Matched conditions: STAGE IVA LUNG CANCER AJCC V8
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Mar 10, 2026 12:53 UTC